[A26-76] Selumetinib (plexiform neurofibromas in neurofibromatosis type 1, 1 to < 3 years) – Addendum to Project A26-09
Last updated 06.08.2026
Project no.:
A26-76
Commission:
Commission awarded on 23.06.2026 by the Federal Joint Committee (G-BA).
Report type:
Addendum
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Cancer
Indication:
Treatment of symptomatic, inoperable plexiform neurofibromas in paediatric patients with neurofibromatosis type 1, aged 1 to < 3 years
Result of dossier assessment:
Unchanged after addendum: Added benefit not proven
Note:
If the need for additional work on a project commissioned by the G-BA arises during consultations, IQWiG submits an addendum. The subsequent decides on the extent of the added benefit concludes the early benefit assessment.
DOI:
https://doi.org/10.60584/A26-76
| Project no. | Title | Status |
|---|---|---|
| A26-09 | Selumetinib (plexiform neurofibromas in neurofibromatosis type 1, 1 to < 3 years) – Benefit assessment according to §35a Social Code Book V | Commission completed |
Federal Joint Committee (G-BA)
06-08-2026 A G-BA decision was published.
G-BA documents on this decision